Table 4.
Tests | Patient number (n) | Sensitivity (%) | Specificity (%) |
---|---|---|---|
KRAS MAF in PB or PC tissue |
43 | 42 | 100 |
KRAS MAF in ctDNA | 93 | 47 | 80 |
CA19-9 | 100 | 76 | 85 |
Combination assay of ctDNA and CA19-9 |
93 | 82 | 81 |
MAF, mutant allele fraction; ctDNA, circulating tumor DNA.